Tg Therapeutics (TGTX) EBIAT (2016 - 2025)
Historic EBIAT for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $390.9 million.
- Tg Therapeutics' EBIAT rose 997461.34% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 321523.95%. This contributed to the annual value of $23.4 million for FY2024, which is 8452.49% up from last year.
- As of Q3 2025, Tg Therapeutics' EBIAT stood at $390.9 million, which was up 997461.34% from $28.2 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' EBIAT registered a high of $390.9 million during Q3 2025, and its lowest value of -$93.3 million during Q4 2021.
- For the 5-year period, Tg Therapeutics' EBIAT averaged around -$5.9 million, with its median value being -$35.8 million (2022).
- Per our database at Business Quant, Tg Therapeutics' EBIAT crashed by 9659.44% in 2024 and then skyrocketed by 997461.34% in 2025.
- Tg Therapeutics' EBIAT (Quarter) stood at -$93.3 million in 2021, then increased by 15.93% to -$78.5 million in 2022, then surged by 81.63% to -$14.4 million in 2023, then surged by 261.84% to $23.3 million in 2024, then surged by 1575.43% to $390.9 million in 2025.
- Its last three reported values are $390.9 million in Q3 2025, $28.2 million for Q2 2025, and $5.1 million during Q1 2025.